ProQR Therapeutics (PRQR) Current Deferred Revenue (2014 - 2025)

ProQR Therapeutics' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $20.4 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue fell 12.86% year-over-year to $20.4 million; the TTM figure through Dec 2025 stood at $20.4 million (down 12.86% YoY), while the FY2025 annual figure was $20.4 million, down 12.86% from the prior year.
• Current Deferred Revenue came in at $20.4 million for Q4 2025 at ProQR Therapeutics, down from $23.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $23.4 million in Q4 2024 to a low of $5.8 million in Q4 2022.
• A 5-year average of $15.5 million and a median of $20.4 million in 2025 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 601.1% in 2021 and fell 12.86% in 2025, its largest moves.
• ProQR Therapeutics' Current Deferred Revenue stood at $5.9 million in 2021, then slipped by 1.64% to $5.8 million in 2022, then soared by 284.54% to $22.1 million in 2023, then climbed by 5.95% to $23.4 million in 2024, then dropped by 12.86% to $20.4 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $20.4 million, $23.4 million, and $22.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison